P.o.v Itch Relief Body
Dimethicone, Menthol
Apollo Health And Beauty Care Inc.
Human Otc Drug
NDC 63148-562P.o.v Itch Relief Body also known as Dimethicone, Menthol is a human otc drug labeled by 'Apollo Health And Beauty Care Inc.'. National Drug Code (NDC) number for P.o.v Itch Relief Body is 63148-562. This drug is available in dosage form of Lotion. The names of the active, medicinal ingredients in P.o.v Itch Relief Body drug includes Dimethicone - 50 mg/mL Menthol - 5 mg/mL . The currest status of P.o.v Itch Relief Body drug is Active.
Drug Information:
| Drug NDC: | 63148-562 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | P.o.v Itch Relief Body |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Dimethicone, Menthol |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Apollo Health And Beauty Care Inc. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Lotion |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | DIMETHICONE - 50 mg/mL
MENTHOL - 5 mg/mL
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 28 Mar, 2018 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 24 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part347 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Apollo Health and Beauty Care Inc.
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 1053386
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UPC: | 0067153948979
|
| UPC stands for Universal Product Code. |
| NUI: | N0000010282
|
| Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT). |
| UNII: | 92RU3N3Y1O
L7T10EIP3A
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
| Pharmacologic Class PE: | Skin Barrier Activity [PE]
|
| Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`. |
| Pharmacologic Class: | Skin Barrier Activity [PE]
|
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 63148-562-14 | 414 mL in 1 BOTTLE, PLASTIC (63148-562-14) | 28 Mar, 2018 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose skin protectant, anti-itch
Product Elements:
P.o.v itch relief body dimethicone, menthol dimethicone dimethicone menthol menthol water cetostearyl alcohol cetyl alcohol polysorbate 60 distearyldimonium chloride glycerin stearamidopropyl pg-dimonium chloride phosphate petrolatum aloe vera leaf stearyl alcohol steareth-2 steareth-21 .alpha.-tocopherol acetate, dl- edetate sodium benzyl alcohol iodopropynyl butylcarbamate
Indications and Usage:
Uses temporarily protects and helps relieve chapped or cracked skin. temporarily relieves itching associated with: minor skin irritations, minor burns, rashes due to poison ivy, oak and sumac insect bites sunburn
Warnings:
Warnings for external use only when using this product avoid contact with eyes. if contact occurs, rinse thoroughly with water. do not use on deep or puncture wournds animal bites serious burns stop use and ask a doctor if condition worsens symptoms persist for more than 7 days or clear up and occur again within a few days redness, irritation, swelling or pain persists or increases keep out of reach of children. in case of accidental ingestion, get medical help or contact a poison control center immediately.
Do Not Use:
Warnings for external use only when using this product avoid contact with eyes. if contact occurs, rinse thoroughly with water. do not use on deep or puncture wournds animal bites serious burns stop use and ask a doctor if condition worsens symptoms persist for more than 7 days or clear up and occur again within a few days redness, irritation, swelling or pain persists or increases keep out of reach of children. in case of accidental ingestion, get medical help or contact a poison control center immediately.
When Using:
When using this product avoid contact with eyes. if contact occurs, rinse thoroughly with water. do not use on deep or puncture wournds animal bites serious burns stop use and ask a doctor if condition worsens symptoms persist for more than 7 days or clear up and occur again within a few days redness, irritation, swelling or pain persists or increases keep out of reach of children. in case of accidental ingestion, get medical help or contact a poison control center immediately.
Dosage and Administration:
Directions apply as needed
Stop Use:
Stop use and ask a doctor if condition worsens symptoms persist for more than 7 days or clear up and occur again within a few days redness, irritation, swelling or pain persists or increases keep out of reach of children. in case of accidental ingestion, get medical help or contact a poison control center immediately.
Package Label Principal Display Panel:
Label copy image of the label
Further Questions:
Questions or comments? 1-866-695-3030